“Discussion: Recent observations by Ramakrishnan et al. suggest that the inhaled corticosteroid budesonide reduces clinical recovery times and prevents progression and clinical deterioration during mild COVID-19 infection… [W]e observed significant reduction of viral titers for all viral variants in vitro when cells were treated with 25 µM budesonide. These results are in accordance with previous studies that demonstrated the suppression of SARS-CoV-2 and MERS-CoV RNA copy number by targeting the viral replication–transcription complex.”
All articles published by MDPI are made immediately available worldwide under an open access license. This means: everyone has free and unlimited access to the full-text of all articles published in MDPI journals; everyone is free to re-use the published material if proper accreditation/citation of the original publication is given; Source: https://www.mdpi.com/openaccess